Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 239-898-6 | CAS number: 15793-73-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Oral:
LD50 (Pigment Orange 34, nano form) >15000 mg/kg
LD50 (strucrue analogue Pigment Orange 13, nano form) >2100 mg/kg
Inhalation:
Waiving
Dermal:
LD50 (strucrue analogue Pigment Orange 38, nano form) >2000 mg/kg
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 16 Mar 1977 to 30 Mar 1977
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: basic data given, comparable to guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Remarks:
- GLP was not compulsory at the time the study was conducted
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 97-107 g
- Fasting period before study: 16 h before and 2 h after dosing
- Diet (ad libitum): Altromin 1324 (Altromin, Lage/Lippe, Germany)
- Water (ad libitum): tap water
- Route of administration:
- oral: gavage
- Vehicle:
- other: sesame oil
- Doses:
- 15000 mg/kg bw as 25% suspension in sesame oil
- No. of animals per sex per dose:
- 10 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations performed, but not stated in detail; weighing was performed weekly
- Necropsy of survivors performed: yes (macroscopic examination) - Statistics:
- not performed
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 15 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no animal died after gavage of the highest applicable dose
- Mortality:
- no deaths
- Clinical signs:
- other: After dosing the animals showed ruffled fur and crouched posture
- Gross pathology:
- no treatment-related effects
- Other findings:
- The coloured test item was excreted in faeces
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study the LD50 was > 15000 mg/kg bw in female rats.
- Executive summary:
Female Wistar-rats were subjected to test acute oral toxicity. The test substance was administered by gavage in doses of 15000 mg/kg bw. After dosing the animals showed ruffled fur and crouched posture. No animal died during the 14 day observation period, resulting in a LD50 > 15000 mg/kg bw. Necroscopy revealed no macroscopic organ alterations.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 30 Oct 1980 to 13 Nov 1980
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: basic data given, comparable to guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Remarks:
- no (GLP was not compulsory at the time the study was conducted)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 200-210 g
- Fasting period before study: 16 h before and 2 h after dosing
- Housing: in groups
- Diet (ad libitum): Altromin 1324 (Altromin, Lage/Lippe, Germany)
- Water (ad libitum): tap water - Route of administration:
- oral: gavage
- Vehicle:
- water
- Doses:
- 5000 mg/kg as 25% aqueous suspension
- No. of animals per sex per dose:
- 10 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations performed, but not stated in detail; weighing was performed weekly
- Necropsy of survivors performed: yes (macroscopic examination) - Statistics:
- not performed
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 100 mg/kg bw
- Based on:
- other: submission substance
- Remarks on result:
- other: The test item contained 42% of the submission substance, i.e. 5000 mg test item/kg bw applied correspond to 2100 mg submission substance/kg bw. resulting in a LD50 of >2100 mg/kg bw.
- Mortality:
- no deaths
- Clinical signs:
- other: no treatment-related effects
- Gross pathology:
- no treatment-related effects
- Other findings:
- no treatment-related effects
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study the LD50 was > 5000 mg test item/kg bw (>2100 mg submission substance/kg bw).
- Executive summary:
Female Wistar-rats were subjected to test acute oral toxicity. The test substance was administered by gavage in doses of 5000 mg/kg bw.. No animal died during the 14 day observation period, resulting in a LD50 >5000 mg test item/kg bw, corresponding to a LD50 >2100 mg/kg bw submission substance. No further toxic effects were observed.
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
[Please provide information for all of the points below. Indicate if further information is included as attachment to the same record, or elsewhere in the dataset (insert links in 'Cross-reference' table)]
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
Please refer to attached read across justification document (Chapter 13).
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
Please refer to attached read across document (Chapter 13).
3. ANALOGUE APPROACH JUSTIFICATION
Please refer to attached read across justification document (Chapter 13).
4. DATA MATRIX
Please refer to attached read across justification document (Chapter 13). - Reason / purpose for cross-reference:
- read-across source
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 100 mg/kg bw
- Based on:
- other: submission substance
- Remarks on result:
- other: The test item contained 42% of the submission substance, i.e. 5000 mg test item/kg bw applied correspond to 2100 mg submission substance/kg bw. resulting in a LD50 of >2100 mg/kg bw.
- Mortality:
- no deaths
- Clinical signs:
- other: no treatment-related effects
- Gross pathology:
- no treatment-related effects
- Other findings:
- no treatment-related effects
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study the LD50 was > 5000 mg test item/kg bw (>2100 mg submission substance/kg bw).
- Executive summary:
Female Wistar-rats were subjected to test acute oral toxicity. The test substance was administered by gavage in doses of 5000 mg/kg bw.. No animal died during the 14 day observation period, resulting in a LD50 >5000 mg test item/kg bw, corresponding to a LD50 >2100 mg/kg bw submission substance. No further toxic effects were observed.
Referenceopen allclose all
No signs of intoxication were observed, macroscopic examination revealed no effects
No signs of intoxication were observed, macroscopic examination revealed no effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 29 MAR 2012 to 18 APR 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study (OECD 402), GLP compliant study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Sulzfeld, Germany
- Age at study initiation: males: 10-12 weeks; females: 8-10 weeks
- Weight at study initiation: males: 220-238 g; females: 213-224 g
- Free access to Altromin 1324 maintenance diet for rats and mice (lot no. 1114)
- Free access to tap water, sulphur acidified to a pH value of approximately 2.8 (drinking water, municipal residue control,
microbiological controls at regular intervals)
- The animals were kept individually in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding (lot no. 110811)
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least five days) under laboratory conditions
ENVIRONMENTAL CONDITIONS
- Full barrier in an air-conditioned room
- Temperature: 22 +/- 3 °C
- Relative humidity: 55 +/- 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 x / hour - Type of coverage:
- semiocclusive
- Vehicle:
- other: Aqua ad injectionem
- Details on dermal exposure:
- Preparation of the Animals:
The animals were marked for individual identification by tail painting.
Approximately 24 hours before the test, the fur was removed from the dorsal area of the trunk using an electric clipper.
Care was taken to avoid abrading the skin, and only animals with healthy intact skin were used.
No less than 10% of the body surface was cleared for the application.
Prior to the application a detailed clinical observation was made of all animals.
Application:
In order to ensure good skin contact, the test item was moistened with the vehicle.
The test item was applied at a single dose, uniformly over an area which was approximately 10% of the total body surface.
The test item was held in contact with the skin by a dressing throughout a 24-hour period. The dressing consisted of
a gauze-dressing and non-irritating tape and was fixed with an additional dressing in a suitable manner.
At the end of the exposure period the residual test item was removed using aqua ad injectionem. - Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg body weight
- No. of animals per sex per dose:
- 5
- Control animals:
- not required
- Details on study design:
- Observation period:
All animals were observed for 14 days after dosing
Weight Assessment:
The animals were weighed on day 1 (prior to the application) and on days 8 and 15.
Clinical Examination:
careful clinical examination was made several times on the day of dosing (at least once during the first 30 minutes
and with special attention given during the first 4 hours post-dose). As soon as symptoms were noticed they were recorded.
Thereafter, the animals were observed for clinical signs once daily until the end of the observation period. All abnormalities were recorded.
Cageside observations included changes in the skin and fur, eyes and mucous membranes. Also respiratory, circulatory,
autonomic and central nervous systems and somatomotor activity and behaviour pattern were examined. Attention was
directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Pathology:
At the end of the observation period the surviving animals were sacrificed with an overdosage of pentobarbital injected
intraperitoneally (Narcoren®, Merial) at the dosage of approximately 8 mL/kg bw. All animals were subjected to gross necropsy.
All gross pathological changes were recorded and in case of findings the tissues were preserved for a possible histopathological evaluation.
The preserved tissues of which no histopathological evaluation was made will be discarded 3 months after the release
of the final report unless otherwise agreed upon with the sponsor.
Evaluation of Results:
Individual reactions of each animal were recorded at each time of observation.
Toxic response data were recorded by sex and dose level.
Nature, severity and duration of clinical observations were described.
The body weight changes were summarised in a tabular form.
Necropsy findings were described. - Statistics:
- According to OECD guidelines, the biological relevance of the results is the criterion for the interpretation of results,
a statistical evaluation of the results is not regarded as necessary. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no mortality was observed during the observation period
- Mortality:
- No mortality was observed
- Clinical signs:
- other: No treatment-related effects were observed.
- Gross pathology:
- No treatment-related effects were observed.
- Other findings:
- No erythema or oedema was observed.
Eschar was observed in one male on day 12. Since this temporary effect was limited to a single animal and
a very short time period and since examination was complicated by test item residues this phenomenon was
not assumed to be a sign of irritation. - Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of the present study, single dermal application of the test item to rats up to 2000 mg/kg body weight was associated with neither mortality nor signs of toxicity or irritation. The dermal LD50 was determined to be > 2000 mg / kg body weight.
- Executive summary:
An acute dermal toxicity test according to OECD guideline 402 has been performed with male and female Wistar rats (5 per sex per dose group). Animals were exposed for 24 hours to 2000 mg/kg bw to the test item under semi-occlusive conditions.
Results per Step
Sex
Dose
(mg/kg bw)Number
of AnimalsNumber
of Intercurrent Deathsmale
2000
5
0
female
2000
5
0
Signs of toxicity related to dose level used, time of onset and duration:
No treatment-related effects were observed.
Effect on organs (related to dose level):
No treatment-related effects were observed.
Signs of irritation:
No erythema or oedema was observed.
Eschar was observed in one male on day 12. Since this temporary effect was limited to a single animal and a very short time period
and since examination was complicated by test item residues this phenomenon was not assumed to be a sign of irritation.
Conclusion
Under the conditions of the present study, single dermal application of the test item to rats up
to 2000 mg/kg body weight was associated with neither mortality nor signs of toxicity or irritation.
The dermal LD50 was determined to be > 2000 mg / kg body weight.- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
[Please provide information for all of the points below. Indicate if further information is included as attachment to the same record, or elsewhere in the dataset (insert links in 'Cross-reference' table)]
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
Please refer to attached read across justification document (Chapter 13).
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
Please refer to attached read across document (Chapter 13).
3. ANALOGUE APPROACH JUSTIFICATION
Please refer to attached read across justification document (Chapter 13).
4. DATA MATRIX
Please refer to attached read across justification document (Chapter 13). - Reason / purpose for cross-reference:
- read-across source
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no mortality was observed during the observation period
- Mortality:
- No mortality was observed
- Clinical signs:
- other: No treatment-related effects were observed.
- Gross pathology:
- No treatment-related effects were observed.
- Other findings:
- No erythema or oedema was observed.
Eschar was observed in one male on day 12. Since this temporary effect was limited to a single animal and
a very short time period and since examination was complicated by test item residues this phenomenon was
not assumed to be a sign of irritation. - Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of the present study, single dermal application of the test item to rats up to 2000 mg/kg body weight was associated with neither mortality nor signs of toxicity or irritation. The dermal LD50 was determined to be > 2000 mg / kg body weight.
- Executive summary:
An acute dermal toxicity test according to OECD guideline 402 has been performed with male and female Wistar rats (5 per sex per dose group). Animals were exposed for 24 hours to 2000 mg/kg bw to the test item under semi-occlusive conditions.
Results per Step
Sex
Dose
(mg/kg bw)Number
of AnimalsNumber
of Intercurrent Deathsmale
2000
5
0
female
2000
5
0
Signs of toxicity related to dose level used, time of onset and duration:
No treatment-related effects were observed.
Effect on organs (related to dose level):
No treatment-related effects were observed.
Signs of irritation:
No erythema or oedema was observed.
Eschar was observed in one male on day 12. Since this temporary effect was limited to a single animal and a very short time period
and since examination was complicated by test item residues this phenomenon was not assumed to be a sign of irritation.
Conclusion
Under the conditions of the present study, single dermal application of the test item to rats up
to 2000 mg/kg body weight was associated with neither mortality nor signs of toxicity or irritation.
The dermal LD50 was determined to be > 2000 mg / kg body weight.
Referenceopen allclose all
Absolute Body Weights in g and Body Weight Gain in %
Dose: 2000 mg/kg body weight |
||||
Animal No. / Sex |
g |
g |
g |
% |
21 / male |
220 |
232 |
256 |
16 |
22 / male |
231 |
253 |
285 |
23 |
23 / male |
238 |
256 |
284 |
19 |
24 / male |
230 |
239 |
259 |
13 |
25 / male |
231 |
258 |
291 |
26 |
26 / female |
216 |
224 |
220 |
2 |
27 / female |
213 |
212 |
219 |
3 |
28 / female |
233 |
230 |
238 |
2 |
29 / female |
224 |
224 |
236 |
5 |
30 / female |
219 |
218 |
220 |
0 |
LD50
Dose (Unit)
|
Number of Animals Investigated |
Number of Intercurrent Deaths |
LD50 |
2000 mg/kg bw |
5 males |
0 |
> 2000 mg/kg bw |
2000mg/kg bw |
5 females |
0 |
> 2000 mg/kg bw |
bw = body weight
Absolute Body Weights in g and Body Weight Gain in %
Dose: 2000 mg/kg body weight |
||||
Animal No. / Sex |
g |
g |
g |
% |
21 / male |
220 |
232 |
256 |
16 |
22 / male |
231 |
253 |
285 |
23 |
23 / male |
238 |
256 |
284 |
19 |
24 / male |
230 |
239 |
259 |
13 |
25 / male |
231 |
258 |
291 |
26 |
26 / female |
216 |
224 |
220 |
2 |
27 / female |
213 |
212 |
219 |
3 |
28 / female |
233 |
230 |
238 |
2 |
29 / female |
224 |
224 |
236 |
5 |
30 / female |
219 |
218 |
220 |
0 |
LD50
Dose (Unit)
|
Number of Animals Investigated |
Number of Intercurrent Deaths |
LD50 |
2000 mg/kg bw |
5 males |
0 |
> 2000 mg/kg bw |
2000mg/kg bw |
5 females |
0 |
> 2000 mg/kg bw |
bw = body weight
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Justification for classification or non-classification
No classification
Neither in studies witn oral nor dermal exposure any adverse effects were observed at / above limit doses
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
